The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy

Cancer Gene Therapy

Volumn 20, Issue 5, 2013, Pages 308-316

  Huang, Y F ^a   Chen, M J ^b   Wu, M H ^a   Hung, S C ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Adenovirus; Hypoxic culture; Mesenchymal stem cells; Oncolytic virus; Tumor targeting

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; CONDITIONALLY REPLICATING ADENOVIRUS; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TUMOR XENOGRAFT; VIRUS REPLICATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

ADENOVIRIDAE;

EID: 84878011400     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.22     Document Type: Article

References (53)

1. Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004; 11: 643-664. (Pubitemid 39299206)
2. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
3. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
4. Southam CM. Present status of oncolytic virus studies. Trans N Y Acad Sci 1960; 22: 657-673.
5. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887. (Pubitemid 29372413)
6. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg FH, Ezekowitz RA et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002; 5: 275-282. (Pubitemid 34211223)
7. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44. (Pubitemid 27075341)
8. Ye X, Jerebtsova M, Ray PE. Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther 2000; 11: 621-627. (Pubitemid 30134305)
9. Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ. Humoral immune responses against minute virus of mice vectors. J Gene Med 2006; 8: 1141-1150. (Pubitemid 44480405)
10. Chen Y, Yu DC, Charlton D, Henderson DR. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-1567. (Pubitemid 30670607)
11. Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res 2004; 10: 7199-7206. (Pubitemid 39487706)
12. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD et al. Carrier cellbased delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007; 15: 123-130. (Pubitemid 46043657)
13. Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A et al. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther 2007; 15: 1121-1128. (Pubitemid 46813615)
14. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-1537. (Pubitemid 29282962)
15. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11: 1073-1081. (Pubitemid 41486829)
16. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007; 14: 324-333. (Pubitemid 46231926)
17. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64: 5934-5937. (Pubitemid 39129387)
18. Ilett EJ, Barcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 2011; 17: 2767-2776.
19. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-766.
20. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009; 15: 7246-7255.
21. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M et al. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 2010; 17: 289-297.
22. Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther 2010; 18: 1846-1856.
23. Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005; 11: 7749-7756. (Pubitemid 41611618)
24. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35. (Pubitemid 46363893)
25. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011; 117: 459-469.
26. Hung SP, Ho JH, Shih YR, Lo T, Lee OK. Hypoxia promotes proliferation and osteogenic differentiation potentials of human mesenchymal stem cells. J Orthop Res 2012; 30: 260-266.
27. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007; 358: 948-953. (Pubitemid 46802482)
28. Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J Cell Physiol 2001; 187: 345-355. (Pubitemid 32378359)
29. Hung SC, Pochampally RR, Hsu SC, Sanchez C, Chen SC, Spees J et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007; 2: e416.
30. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002; 20: 530-541. (Pubitemid 35463066)
31. Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther 2004; 11: 1126-1136. (Pubitemid 39117308)
32. Deak E, Seifried E, Henschler R. Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol 2010; 29: 514-529.
33. Kang SK, Shin IS, Ko MS, Jo JY, Ra JC. Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cells Int 2012; 2012: 342968.
34. Wynn RF, Hart CA, Corradi-Perini C, O'Neill L, Evans CA, Wraith JE et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004; 104: 2643-2645. (Pubitemid 39434942)
35. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427. (Pubitemid 40981232)
36. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009; 17: 1667-1676.
37. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323. (Pubitemid 27114163)
38. Garcia-Castro J, Trigueros C, Madrenas J, Perez-Simon JA, Rodriguez R, Menendez P. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008; 12: 2552-2565.
39. Shibata KR, Aoyama T, Shima Y, Fukiage K, Otsuka S, Furu M et al. Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion. Stem Cells 2007; 25: 2371-2382. (Pubitemid 47480497)
40. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008; 3: e2213.
41. Wislet-Gendebien S, Leprince P, Moonen G, Rogister B. Regulation of neural markers nestin and GFAP expression by cultivated bone marrow stromal cells. J Cell Sci 2003; 116(Pt 16): 3295-3302. (Pubitemid 37038978)
42. Briquet A, Dubois S, Bekaert S, Dolhet M, Beguin Y, Gothot A. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica 2010; 95: 47-56.
43. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009; 69: 8932-8940.
44. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc 2007; 39: 573-576. (Pubitemid 46386222)
45. Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K et al. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol Ther 2003; 7: 354-365. (Pubitemid 36503859)
46. Choi JW, Lee JS, Kim SW, Yun CO. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 2011; 64: 720-729.
47. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148. (Pubitemid 46348628)
48. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011; 141: 1046-1056.
49. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2012, e-pub ahead of print 22 October. doi: 10. 1038/onc. 2012. 458.
50. Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004; 11: 477-486. (Pubitemid 38902674)
51. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A: 2362-2370. (Pubitemid 26053242)
52. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229-238. (Pubitemid 127667119)
53. Lee RH, Yoon N, Reneau JC, Prockop DJ. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 2012; 11: 825-835.